From thesis to portfolio.
An investment workflow that runs end to end. Hebrides starts from your firm's investment thesis, runs through every deal you analyse, and continues across the portfolio that follows.
Your firm's lens, applied to every deal.
Hebrides takes your sectors, hard passes and the patterns your partners look for as context.
We lead and co-lead Series B and Series C rounds of $5–25M into B2B vertical SaaS companies in North America and the UK. Targets: $5M+ ARR, NRR > 115%, gross margin > 70%.
Hard passes: pre-revenue, hardware-heavy capex, deals where 15–20% ownership isn't achievable.
Your deals, in one workspace.
Hebrides connects to OneDrive or Google Drive (Dropbox coming soon) and reads the deck, the data room, board minutes, transcripts and your internal notes together.
Your structured first read.
Hebrides cross-checks claims across every document, surfaces comparables from public data, flags risks and scores fit against your firm's thesis.
Your follow-up questions, answered.
Hebrides Chat searches the data room and the public web in one place: pull a number, sense-check a claim, find a comparable.
Acme is raising a $65M Series C at a $450M pre-money valuation, implying a $515M post-money and c.12.6% dilution. The pre-money values the company at c.8.3× FY2025 ARR of $54.5M.1
Healthcare IT Series C rounds in 2024–25 typically trade at 7–12× ARR for companies showing 50%+ growth, 130%+ NRR and gross margins above 70%.2,3 Acme's headline metrics (57% growth, 138% NRR, 75.4% GM) sit in the upper quartile of this set.4
Two source documents disagree on R&D allocation. AcmeCorp_CIM.docx allocates 25% ($16.25M); AcmeCorp_QA_Prep.docx allocates 40% ($26.0M).5,6 Worth resolving before committing.
Financials, extracted and benchmarked.
Hebrides pulls the financials out of the data room, finds comparables for the sector and stage, and runs a multiples calculation.
| Range | Multiple | × ARR | = Implied EV |
|---|---|---|---|
| Low | 7.0× | $54.5M | $382M |
| Median | 8.7× | $54.5M | $474M |
| High | 12.0× | $54.5M | $654M |
Your IC memo, drafted before you sit down to write it.
Hebrides writes the first draft from the structured deal, and from there it's a writing workspace for you, your team and Hebrides together.
Series C investment in Acme Corp, a healthcare AI company delivering an FDA-cleared, AI-powered remote patient monitoring (RPM) platform focused on chronic disease management.816
The company has scaled to $54.5M ARR in FY2025 with 57% YoY growth, 75.4% gross margins and 138% NRR across 125 enterprise customers, positioning it in the upper quartile of healthcare IT Series C benchmarks.91024
| Factor | Assessment |
|---|---|
| Unit economics | LTV/CAC 5.3×, payback 11 months, ACV $436k. Path to breakeven by 2027.69 |
| Moat | Data scale (2.8B+ vitals, 480k+ patients), deep EHR integrations, 12–14 issued patents.810 |
| Risks | Execution risk in fast-consolidating RPM market; CMS reimbursement shift.4 |
Your portfolio, reported quarterly.
Hebrides drafts your quarterly LP updates, annual reviews and cross-portfolio analysis from the same structured deals that power your IC memos.
Demo VC ended Q1 2026 with 12 active investments and 3 tracked passes, against $215M deployed across the fund.37 Aggregate ARR across the active portfolio grew 48% YoY, with three companies now operating ahead of plan.11
| Company | ARR | Growth | Status |
|---|---|---|---|
| Acme Corp | $54.5M | 57% | On track |
| Beta Inc | $32.0M | 42% | Watch |
| Gamma Ltd | $68.2M | 81% | Outperform |
| Delta AI | $12.4M | 125% | Outperform |
Questions investors ask.
Who is Hebrides for?
Hebrides is built for professional investors: family offices, venture capital firms and private equity teams. It is designed for lean investment teams that want institutional analytical depth without adding headcount.
What does Hebrides do?
Hebrides structures the documents behind a deal into one workspace, then runs the analysis end to end: a structured first read of the data room, a sourced chat over your documents and the public web, valuations, and AI-drafted IC memos and portfolio reports.
Where does Hebrides get its information?
From the documents you connect to a deal, through OneDrive or Google Drive, or uploaded directly. Hebrides can also draw on publicly available information. Insights and answers link back to the sources they came from.
How does Hebrides value a company?
It extracts the financials from the data room and triangulates value across three methods: DCF, public-market comparables and the VC method, so the range is grounded in more than a single approach.
Is our data used to train AI models?
No. Your deal information is never used to train models. Hebrides is built around the security bar that family offices, VCs and PE firms expect, with role-based access controls and audit logs.
Can the whole team work in Hebrides together?
Yes. Hebrides supports Admin, Manager and User roles, granular access control per deal and portfolio, and shared reports.
A structured, reliable read on every deal.
All your deal data in one place, with the analysis run end to end.